Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer – Targeted Oncology

Source: Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer – Targeted Oncology

Sukhmani Padda, MD, an assistant professor of medicine at Stanford Cancer Institute, discusses the role of immunotherapy in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Immunotherapy has not been the biggest hit yet for this patient population, says Padda. However, it can play a role in a more selective patient population.

Immunotherapy should only be considered for these patients with EGFR-mutant NSCLC after all targeted therapies have been tried, as well as a platinum doublet chemotherapy. However, even in patients with high PD-L1 expression, the response rates with immunotherapy have not been that high.

Padda cautions that physicians seeing these patients in the clinic should look for signs of early progression.

Published at Tue, 26 Mar 2019 20:05:00 +0000